| Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis |
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis |
globenewswire.com |
2025-04-29 20:05:00 |
Czytaj oryginał (ang.) |
| Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones |
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones Annual General Meeting scheduled for Friday, June 6, 2025, in Paris, France Phase 3 ABTECT induction trials remain on track: enrollment completion expected in Q2 2025, with top-line induction results expected in Q3 2025 PARIS, France – April 22, 2025 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that the upcoming Annual General Meeting will be held on June 6, 2025, in Paris, France. Additional information and preparatory documents for this Annual General Meeting will be made available in the coming weeks in accordance with applicable legal and regulatory requirements. |
globenewswire.com |
2025-04-22 20:05:00 |
Czytaj oryginał (ang.) |
| Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors |
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors Industry veteran brings deep immunology expertise ahead of key Phase 3 data readout in ulcerative colitis expected in Q3 2025 PARIS, France, April 22, 2025, 10:00 pm CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Dominik Höchli, MD to the Board of Directors of Abivax, effective immediately. Dr. Höchli brings over two decades of leadership experience in global biopharma, most notably a 20-year tenure at AbbVie/Abbott, where he served as Vice President of Global Marketing for Immunology and later as Head of Global Medical Affairs. |
globenewswire.com |
2025-04-22 20:00:00 |
Czytaj oryginał (ang.) |
| Abivax publishes financial reports with the French and U.S. securities regulatory agencies |
Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – March 26, 2025 – 10:05 PM CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announces the filing of its Universal Registration Document (Document d'Enregistrement Universel) with the French Financial Market Authorities, Autorité des Marchés Financiers (AMF), and the filing of its Annual Report (20-F) with the U.S. Securities and Exchange Commission (SEC) on March 24, 2025. The Universal Registration Document includes the 2024 annual financial report, the management report including the report on corporate governance, as well as the reports of the statutory auditors. |
globenewswire.com |
2025-03-26 19:05:00 |
Czytaj oryginał (ang.) |
| Abivax Announces Full Year 2024 Financial Results |
Abivax Announces Full Year 2024 Financial Results • Cash balance of EUR 144.2M as of December 31, 2024; cash runway into Q4 2025 Full enrollment in Phase 3 ABTECT trial evaluating obefazimod for moderately to severely active ulcerative colitis (“UC”) expected in Q2 2025 with top-line results from the 8-week induction trials expected in Q3 2025 PARIS, France – March 24, 2025 – 8:30 AM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for chronic inflammatory diseases, announced today its full-year financial results, as of December 31, 2024. The 2024 financial statements, approved by the Company's Board of Directors on March 20, 2025, have been audited by the Company's statutory auditors, and the financial reports will be filed with the French and U.S. securities regulatory authorities, respectively, on March 24, 2025. |
globenewswire.com |
2025-03-24 05:30:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts See a 360.53% Upside in Abivax SA Sponsored ADR (ABVX): Can the Stock Really Move This High? |
The consensus price target hints at a 360.5% upside potential for Abivax SA Sponsored ADR (ABVX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2025-02-27 12:55:31 |
Czytaj oryginał (ang.) |
| Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 |
Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 Event to Feature Renowned Gastroenterologist Dr. David Rubin, Highlighting the Ulcerative Colitis Treatment Landscape and Abivax's Pivotal ABTECT Phase 3 Trial PARIS, France – February 21, 2025 – 8:30 AM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for chronic inflammatory diseases, today announced it will host a Key Opinion Leader (KOL) Investor Webcast on Monday, March 17, 2025, at 9:00 a.m. EDT (2:00 p.m. |
globenewswire.com |
2025-02-21 04:30:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Abivax SA Sponsored ADR (ABVX) Could Surge 427.9%: Read This Before Placing a Bet |
The mean of analysts' price targets for Abivax SA Sponsored ADR (ABVX) points to a 427.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2025-02-11 12:56:16 |
Czytaj oryginał (ang.) |
| Here's Why Abivax SA Sponsored ADR (ABVX) is Poised for a Turnaround After Losing -19.81% in 4 Weeks |
Abivax SA Sponsored ADR (ABVX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
zacks.com |
2025-01-30 12:35:45 |
Czytaj oryginał (ang.) |
| Abivax Publishes 2025 Financial Calendar |
Abivax Publishes 2025 Financial Calendar PARIS, France – January 28, 2025 – 8:30 AM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company developing innovative therapies to address chronic inflammatory diseases, today published its expected 2025 financial communications calendar. Monday, March 24, 2025 (after US Market closes) 2024 Annual Business and Financial Report (as of December 31, 2024) Press Release Universal Registration Document (Euronext) Annual Report on Form 20-F Monday, June 2, 2025 (after US Market closes) 2025 Q1 Financial Results (as of March 31, 2025) Press Release Report on Form 6-K Friday, June 6, 2025 2025 Annual General Meeting (AGM) Live meeting in Paris, France Monday, August 11, 2025 (after US Market closes) 2025 Half-Year Business and Financial Report (as of June 30, 2025) Press Release Half-Year Financial Report (Euronext) Report on Form 6-K Monday, December 15, 2025 (after US Market closes) 2025 Q3 Financial Results (as of September 30, 2025) Press Release Report on Form 6-K About Abivax Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. |
globenewswire.com |
2025-01-28 04:30:00 |
Czytaj oryginał (ang.) |
| Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn's and Colitis Organization 20th Annual Congress |
Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn's and Colitis Organization 20th Annual Congress |
globenewswire.com |
2025-01-23 18:05:00 |
Czytaj oryginał (ang.) |
| Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment |
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment Phase 3 ABTECT Trial evaluating obefazimod for moderately to severely active ulcerative colitis (“UC”) reaches 1,003 of 1,224 participants, representing 82% of target enrollment. Enrollment completion expected in Q2 2025. |
globenewswire.com |
2025-01-09 13:35:00 |
Czytaj oryginał (ang.) |
| Abivax Announces a Change to the Composition of its Board of Directors |
Abivax Announces a Change to the Composition of its Board of Directors PARIS, France, December 23, 2024, 10:05 PM CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, today announced that Dr. Philippe Pouletty, representative of Truffle Capital, tendered his resignation as director of the Company effective on December 31, 2024. Dr. Philippe Pouletty's decision is directly related to his appointment last week as Chairman and acting Chief Executive Officer of a French listed biotechnology company in the field of plastics recycling. |
globenewswire.com |
2024-12-23 18:05:00 |
Czytaj oryginał (ang.) |
| Abivax Establishes an At-the-Market (ATM) Program on Nasdaq |
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq PARIS, France, November 19, 2024 – 10:30PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq - ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, today announced the implementation of an At-The-Market program (“ATM Program”) allowing the Company to issue and sell, including with unsolicited investors who have expressed an interest, ordinary shares in the form of American Depositary Shares (“ADS”), each ADS representing one ordinary share, nominal value €0.01 per share, of the Company, with aggregate gross sales proceeds of up to $150,000,000 (subject to French regulatory limits and within the limits of the investors' requests expressed in the context of the program), from time to time, pursuant to the terms of an equity distribution agreement with Piper Sandler & Co. (“Piper Sandler”), acting as sales agent. The timing of any issuances in the form of ADSs will depend on a variety of factors. |
globenewswire.com |
2024-11-19 18:30:00 |
Czytaj oryginał (ang.) |
| Abivax presents third quarter 2024 key financial information |
Abivax presents third quarter 2024 key financial information PARIS, France, November 14, 2024, 10:00 p.m. CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its key financial information for the quarter ended September 30, 2024. |
globenewswire.com |
2024-11-14 18:01:00 |
Czytaj oryginał (ang.) |
| Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax |
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax |
globenewswire.com |
2024-11-13 18:01:00 |
Czytaj oryginał (ang.) |
| Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation |
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation |
globenewswire.com |
2024-10-07 20:01:00 |
Czytaj oryginał (ang.) |
| Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease |
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease PARIS, France, October 3, 2024 – 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX; Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the first patient was enrolled in its Phase 2b ENHANCE-CD (NCT06456593) trial evaluating obefazimod in patients with Crohn's disease (CD). |
globenewswire.com |
2024-10-03 20:01:00 |
Czytaj oryginał (ang.) |
| Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance |
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance |
globenewswire.com |
2024-10-03 06:31:00 |
Czytaj oryginał (ang.) |
| Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024 |
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024 Professor Bruce E. Sands, MD to present oral presentation of Phase 2b, open-label, maintenance efficacy and safety data at weeks 48 and 96 among week 8 induction non-responders in obefazimod-treated patients with moderately to severely active ulcerative colitis (UC) Two moderated poster presentations highlighting corticosteroid-free efficacy and safety data of obefazimod at weeks 48 and 96 of an open-label maintenance trial, as well as the impact of obefazimod induction therapy on combined histologic and endoscopic outcomes at week 8 in patients with UC PARIS, France, September 26, 2024 – 08:30 a.m. |
globenewswire.com |
2024-09-26 06:30:00 |
Czytaj oryginał (ang.) |
| Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model |
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model |
globenewswire.com |
2024-09-25 20:01:00 |
Czytaj oryginał (ang.) |
| Is Abivax SA Sponsored ADR (ABVX) Outperforming Other Medical Stocks This Year? |
Here is how Abivax SA Sponsored ADR (ABVX) and PetIQ (PETQ) have performed compared to their sector so far this year. |
zacks.com |
2024-09-13 14:46:12 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe Abivax SA Sponsored ADR (ABVX) Could Rally 193.62%: Here's is How to Trade |
The mean of analysts' price targets for Abivax SA Sponsored ADR (ABVX) points to a 193.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2024-09-12 14:55:36 |
Czytaj oryginał (ang.) |
| Abivax presents first-half 2024 financial results |
Abivax presents first-half 2024 financial results Cash balance of EUR 222M at June 30, 2024; cash runway in to Q4 2025 PARIS, France, September 9, 2024, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its 2024 half-year financial results, as of June 30, 2024. |
globenewswire.com |
2024-09-09 20:01:00 |
Czytaj oryginał (ang.) |
| Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone |
Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) surpassed the 600-patient enrollment milestone confirming ABTECT currently on pace to reach full enrollment in early Q1 2025 To date, baseline participants baseline characteristics and trial trends in line with observations from Phase 2b trial PARIS, France, August 6, 2024, 8:30 a.m. CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announced today that in July 2024, the 600th participant was enrolled in the Phase 3 ABTECT Trial. |
globenewswire.com |
2024-08-06 06:30:00 |
Czytaj oryginał (ang.) |
| Abivax Provides Operational and Key Program Update |
Abivax Provides Operational and Key Program Update Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1 2025 Top-line results from the ABTECT 8-week induction trial expected early Q2 2025, with 44-week maintenance data on pace to read out in Q1 2026; timing assumptions for New Drug Application (NDA) submission remain unchanged Continued progress on pre-clinical combination therapy program Sylvie Grégoire named Chair of Abivax's Board of Directors; Dr. Fabio Cataldi named Chief Medical Officer and Dr. David Zhang named Chief Strategy Officer Cash position allows for runway into Q4 2025 through ABTECT 8-week induction top-line results PARIS, France, July 15, 2024, 10:00 p.m. CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax”, “we” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today provided an update on the progress of key clinical and preclinical programs and its leadership and operational updates. |
globenewswire.com |
2024-07-15 20:00:00 |
Czytaj oryginał (ang.) |
| Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting |
PARIS, France, June 4, 2024 – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, held its ordinary and extraordinary general meeting of shareholders on May 30, 2024 (the “General Meeting”), which was chaired by Mr. Marc de Garidel, CEO and Chairman of the Board of Directors of Abivax (“Board”). |
globenewswire.com |
2024-06-04 20:10:00 |
Czytaj oryginał (ang.) |
| ABIVAX Société Anonyme (AAVXF) Q4 2023 Earnings Call Transcript |
ABIVAX Société Anonyme (OTC:AAVXF) Q4 2023 Earnings Conference Call April 8, 2024 8:30 AM ET Company Participants Patrick Malloy - SVP, IR Marc de Garidel - CEO Sheldon Sloan - Chief Medical Officer Didier Scherrer - Chief Scientific Officer Conference Call Participants Thomas Smith - Leerink Partners Vikram Purohit - Morgan Stanley Julian Harrison - BTIG Operator Ladies and gentlemen, thank you for standing by. Welcome to ABIVAX Conference Call to discuss 2023 Financial Results and Business Update. |
seekingalpha.com |
2024-04-08 17:25:24 |
Czytaj oryginał (ang.) |
| Abivax reports 2023 financial results and operational update |
Abivax reports 2023 financial results and operational update Raised EUR 500M in 2023, including a EUR 130M capital increase, two structured debt financing transactions aggregating EUR 150M and EUR 223.3M initial public offering on the Nasdaq Global Market Sufficient funds to finance operations into Q4 2025, including through the announcement of top-line data from the Phase 3 ABTECT induction trials of obefazimod in ulcerative colitis (UC) Implementation of U.S. and European operational infrastructure to progress the Company's ongoing clinical and preclinical programs PARIS, France, April 2, 2024, 8:30 a.m. CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced its 2023 annual financial results, as of December 31, 2023, and provided an update on the progress of its development programs. |
globenewswire.com |
2024-04-02 06:30:00 |
Czytaj oryginał (ang.) |
| Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn's and Colitis Organization (ECCO) |
PARIS, FRANCE / ACCESSWIRE / February 13, 2024 / Abivax SA (Euronext Paris:ABVX))(NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that four scientific abstracts on its lead drug candidate, obefazimod for the treatment of moderately to severely active ulcerative colitis (UC), will be presented during the 19th Congress of the European Crohn's and Colitis Organisation (ECCO) on February 21-24, 2024, in Stockholm, Sweden. "We are delighted that all four submitted abstracts have been accepted for presentations at ECCO. |
accesswire.com |
2024-02-13 04:50:00 |
Czytaj oryginał (ang.) |
| Citi Appointed as Depositary Bank for Abivax SA's ADR Program |
LONDON--(BUSINESS WIRE)--Citi, acting through Citibank N.A., has been appointed by Abivax SA (“Abivax”), to act as depositary bank for its initial public offering (the “IPO”) of Abivax's American Depositary Shares (“ADSs” or “ADRs”) representing its ordinary shares. Abivax's ADSs trade on the Nasdaq Global Market under the ticker symbol “ABVX”. The company's underlying ordinary shares are listed on Euronext Paris under the symbol “ABVX”. Each ADS represents one ordinary share of the company. Co. |
businesswire.com |
2023-10-26 08:00:00 |
Czytaj oryginał (ang.) |
| Abivax Announces Closing of its Initial Public Offering on the Nasdaq Global Market |
PARIS, FRANCE / ACCESSWIRE / October 24, 2023 / Abivax SA (Euronext Paris:FR0012333284 - ABVX) (" Abivax " or the " Company "), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announced the closing of its previously announced initial public offering on the Nasdaq Global Market by way of a capital increase of 20,325,500 new ordinary shares (the " New Shares "), consisting of a public offering of 18,699,460 ordinary shares in the form of American Depositary Shares (" ADSs "), each representing the right to receive one ordinary share, in the United States (the " U.S. Offering ") and a concurrent offering of 1,626,040 ordinary shares in certain jurisdictions outside of the United States to certain investors (the " European Private Placement " and together with the U.S. Offering, the " Global Offering "). The offering price was set at $11.60 per ADS in the U.S. Offering and a corresponding offering price of €10.9864 per ordinary share in the European Private Placement. |
accesswire.com |
2023-10-24 20:15:00 |
Czytaj oryginał (ang.) |